(thirdQuint)Metformin With Standard Taxotere and Prednisone in the Treatment of Castration Resistant Prostate Cancer.

 This is a single-arm, non-randomized Phase II trial of docetaxel given every 3 weeks with metformin twice daily and Prednisone twice daily.

 The study duration of this trial is open ended.

 The patient would take the metformin only for as long as they are treated with docetaxel.

.

 Metformin With Standard Taxotere and Prednisone in the Treatment of Castration Resistant Prostate Cancer@highlight

This study is being conducted to determine the effectiveness of standard 3 weekly treatments using docetaxel and prednisone with metformin in patients with castration-resistant metastatic prostate cancer.

 It is also being conducted to determine the levels of toxicity of metformin when added to every 3 weekly docetaxel treatments in patients with endocrine resistent, metastatic prostate cancer.

